CO5580750A2 - Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1ë6--tiomorfolin-4-il)-4-(4-fluor-2-metil(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida - Google Patents

Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1ë6--tiomorfolin-4-il)-4-(4-fluor-2-metil(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida

Info

Publication number
CO5580750A2
CO5580750A2 CO05070753A CO05070753A CO5580750A2 CO 5580750 A2 CO5580750 A2 CO 5580750A2 CO 05070753 A CO05070753 A CO 05070753A CO 05070753 A CO05070753 A CO 05070753A CO 5580750 A2 CO5580750 A2 CO 5580750A2
Authority
CO
Colombia
Prior art keywords
methyl
fluor
phenyl
dioxo
bis
Prior art date
Application number
CO05070753A
Other languages
English (en)
Inventor
Torsten Hoffmann
Emery Fabienne Hoffmann
Sonia Nick
Urs Schwitter
Pius Waldmeier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5580750A2 publication Critical patent/CO5580750A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Nueva modificación cristalina de la 2-(3,5-bis-trifluormetil-fenil)-N-[6-(1,1-dioxo-1?6-tiomorfolin-4-il)-4-(4-fluor-2metil-fenil)-piridin-3-il]-N-metil-isobutiramida caracterizada por el siguiente modelo de difracción por rayos X, obtenido con una radiación CUka A 2? (2teta) = 4,5, 6,4, 7,5, 7,7, 8,0, 8,2, 10,0, 10,2, 10,9, 11,1, 12,9, 13,4, 14,0, 14,5, 15,1, 15,6, 16,2, 16,5, 17,3, 17,5, 18,0, 18,9, 19,3, 19,5, 19,9, 20,1, 20,6, 21,0, 21,4, 22,7, 23,1 y 23,6 y un espectro de infrarrojos con bandas agudas a 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm-1, y en donde el punto de fusión extrapolado (DSC) es de 137,2°C.
CO05070753A 2003-01-31 2005-07-18 Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1ë6--tiomorfolin-4-il)-4-(4-fluor-2-metil(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida CO5580750A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03002134 2003-01-31

Publications (1)

Publication Number Publication Date
CO5580750A2 true CO5580750A2 (es) 2005-11-30

Family

ID=32798734

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05070753A CO5580750A2 (es) 2003-01-31 2005-07-18 Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1ë6--tiomorfolin-4-il)-4-(4-fluor-2-metil(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida

Country Status (28)

Country Link
US (1) US7160881B2 (es)
EP (1) EP1592428B1 (es)
JP (1) JP5026702B2 (es)
KR (1) KR100700421B1 (es)
CN (1) CN100562320C (es)
AR (1) AR042980A1 (es)
AT (1) ATE366576T1 (es)
AU (1) AU2004208483B8 (es)
BR (1) BRPI0406702A (es)
CA (1) CA2514037C (es)
CL (1) CL2004000150A1 (es)
CO (1) CO5580750A2 (es)
DE (1) DE602004007486T2 (es)
ES (1) ES2290666T3 (es)
GT (1) GT200400009A (es)
HR (1) HRP20050664A2 (es)
IL (1) IL169600A (es)
MX (1) MXPA05008171A (es)
MY (1) MY135785A (es)
NO (1) NO20053431L (es)
NZ (1) NZ541243A (es)
PA (1) PA8594601A1 (es)
PE (1) PE20040944A1 (es)
PL (1) PL378404A1 (es)
RU (1) RU2330022C2 (es)
TW (1) TWI293294B (es)
WO (1) WO2004067007A1 (es)
ZA (1) ZA200505567B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002860A1 (en) 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP0737192B1 (en) 1993-12-29 2001-10-31 Merck Sharp & Dohme Ltd. Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
SE1035115T5 (sv) 1999-02-24 2015-08-04 Hoffmann La Roche 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister
DE60210760T2 (de) * 2001-04-23 2006-11-23 F. Hoffmann-La Roche Ag Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
JP5026702B2 (ja) 2012-09-19
DE602004007486D1 (de) 2007-08-23
EP1592428B1 (en) 2007-07-11
JP2006514999A (ja) 2006-05-18
US7160881B2 (en) 2007-01-09
KR100700421B1 (ko) 2007-03-28
KR20050096964A (ko) 2005-10-06
ZA200505567B (en) 2007-05-30
RU2005127216A (ru) 2006-04-10
CA2514037A1 (en) 2004-08-12
BRPI0406702A (pt) 2005-12-20
AR042980A1 (es) 2005-07-13
RU2330022C2 (ru) 2008-07-27
AU2004208483B8 (en) 2008-04-03
MXPA05008171A (es) 2005-10-05
NO20053431L (no) 2005-10-05
TWI293294B (en) 2008-02-11
NZ541243A (en) 2008-04-30
AU2004208483B2 (en) 2008-03-06
PA8594601A1 (es) 2004-09-16
GT200400009A (es) 2004-12-01
CN100562320C (zh) 2009-11-25
ATE366576T1 (de) 2007-08-15
PL378404A1 (pl) 2006-04-03
CA2514037C (en) 2012-03-13
HRP20050664A2 (en) 2006-12-31
CN1744900A (zh) 2006-03-08
TW200510358A (en) 2005-03-16
WO2004067007A1 (en) 2004-08-12
NO20053431D0 (no) 2005-07-14
ES2290666T3 (es) 2008-02-16
MY135785A (en) 2008-06-30
DE602004007486T2 (de) 2008-04-30
US20040186100A1 (en) 2004-09-23
EP1592428A1 (en) 2005-11-09
AU2004208483A1 (en) 2004-08-12
IL169600A (en) 2010-11-30
CL2004000150A1 (es) 2005-01-07
PE20040944A1 (es) 2004-12-14

Similar Documents

Publication Publication Date Title
CO5580750A2 (es) Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1ë6--tiomorfolin-4-il)-4-(4-fluor-2-metil(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida
MXPA06001273A (es) Compuestos novedosos.
EP1772450A4 (en) PROCESS FOR THE MANUFACTURE OF A 1,2-DIHYDROPYRIDINE-2-ONE COMPOUND
RS54569B1 (en) POLYMORPHIC FORMS OF RIFAXIMIN, PROCEDURES FOR ITS MANUFACTURE AND ITS USE IN MEDICINAL PRODUCTS
NO20052755D0 (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmate for dens fremstilling og dens anvendelse.
HK1069395A1 (en) Phthalazinone derivatives 2,3
WO2006014262A3 (en) Indoles having anti-diabetic activity
ATE151758T1 (de) 4-benzoyl-isoxazol derivate, deren herstellung und deren verwendung als herbizide
AU2001276808A1 (en) A crystalline form of celecoxib
PL366986A1 (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide
TW200609228A (en) Substituted n-acyl-2-aminothiazoles
MXPA05009725A (es) Derivados de ftalamida insecticidas.
DOP2004000808A (es) Nueva modificacion cristalina de la 2-(3,5-bis-trifluormetilfenil)-n-[6-(1,1-dioxo-1 6-tiomorfolin-4-il)-4-(4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida
AU2003290121A1 (en) Novel process for the preparation of 2-aminomethylpyridine derivative
CY1108241T1 (el) Πυριδυλσουλφοναμιδο πυριμιδινες για την θεραπεια της διαβητικης νεφροπαθειας
TWI318625B (en) Process for the preparation of 2-aminomethylpyridine derivative
PT1230176E (pt) Utilizacao de materiais refractarios calcinados a base de oxido de estanho para a realizacao de gargantas de fornos de vidro
ATE383357T1 (de) Acylderivate von 5-(2-(4-(1,2 benzisothiazol-3- yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2 - indol-2-on mit neuroleptischer wirkung
MXPA04010500A (es) Imidazopiridinas nitrosadas.
NO20053078D0 (no) Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.
AU2003222627A1 (en) Human il-18 crystal structure
PT755393E (pt) Novas formas cristalinas de 1-¬5-metanossulfonamidoimdolil-2-carbonil|-4-¬3-(1-metiletilamino)-2-piridinil|piperazina
AU2003208687A1 (en) Method of making a heating element of the molybdenum silicide type and a heating element
TW200507012A (en) A doped substrate and method of fabrication
EA200601131A1 (ru) Холодные катоды из углеродных материалов

Legal Events

Date Code Title Description
FC Application refused